Neuromuscular Blocking Drugs and Reversal

Acetylcholine released from the motor nerve binds nicotinic receptors at the neuromuscular junction, opens cation channels, depolarizes the end plate, and initiates skeletal-muscle contraction. Acetylcholinesterase rapidly terminates the signal.

Neuromuscular blocking drugs facilitate tracheal intubation, surgery, and selected mechanical-ventilation strategies. They do not provide unconsciousness, amnesia, or analgesia; adequate anesthesia and monitoring are mandatory.

Succinylcholine is a depolarizing agonist at the nicotinic receptor. Persistent end-plate depolarization initially causes fasciculations and then prevents further effective contraction. Rapid hydrolysis by plasma butyrylcholinesterase gives it a short usual duration.

• Clinically important risks include hyperkalemia, malignant hyperthermia, bradyarrhythmia, myalgia, increased intraocular and intragastric pressure, and prolonged apnea with deficient or atypical butyrylcholinesterase.
• Dangerous hyperkalemia is more likely after major burns, denervation, prolonged immobility, or neuromuscular disease once extrajunctional receptors have proliferated.
• Phase I block is not reversed by acetylcholinesterase inhibition; prolonged exposure can produce a phase II pattern.

Nondepolarizing drugs competitively inhibit acetylcholine at nicotinic receptors without opening the channel. Their effect is potentiated by volatile anesthetics, aminoglycosides, magnesium, acidosis, hypothermia, and several other conditions or drugs.

• Atracurium and cisatracurium undergo organ-independent Hofmann degradation; atracurium causes more histamine release and forms more laudanosine.
• Rocuronium has a relatively rapid onset and is used for routine and rapid-sequence intubation. It is primarily eliminated through hepatic and biliary pathways.
• Vecuronium is an aminosteroid with minimal cardiovascular effects but can be prolonged by organ dysfunction.
• Pancuronium is longer acting, depends substantially on renal elimination, and can cause vagolytic tachycardia.

Clinical signs alone are insensitive for residual paralysis. Quantitative train-of-four monitoring at the adductor pollicis should confirm a ratio of at least 0.9 before extubation after nondepolarizing blockade.

Neostigmine inhibits acetylcholinesterase and increases acetylcholine at both nicotinic and muscarinic synapses. It is paired with an antimuscarinic such as glycopyrrolate or atropine and is most reliable when spontaneous recovery is already present.

Sugammadex encapsulates rocuronium and vecuronium. Its dose depends on measured block depth; it does not reverse benzylisoquinolinium blockers or succinylcholine. Bradycardia and hypersensitivity are important risks.

Primary teaching source: Akram Amer, Pharmacology of Anesthesia Drugs, pages 15-23.

Monitoring and reversal recommendations were aligned with the American Society of Anesthesiologists 2023 practice guideline and current rocuronium and sugammadex prescribing information.

This material is educational and remains a draft until reviewed by a qualified clinician. Local protocols and current product information take precedence for patient care.